NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies

Key Takeaways NVO's Phase III evoke studies showed Rybelsus failed to slow AD progression versus placebo.Rybelsus improved AD-related biomarkers but showed no measurable impact on disease progression.Novo Nordisk will halt the extension phase and present top-line data in December with full results in 2026.Novo Nordisk (NVO) reported disappointing top-line data from the two-year primary analysis of two late-stage studies evaluating Rybelsus (oral semaglutide 14 mg) for early-stage symptomatic Alzheimer’s dis ...